|Other names||Wasting syndrome|
|Specialty||Oncology, Internal Medicine, Physical Medicine and Rehabilitation|
Cachexia (//) is a complex syndrome associated with an underlying illness causing ongoing muscle loss that is not entirely reversed with nutritional supplementation. A range of diseases can cause cachexia, most commonly cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease and AIDS. Systemic inflammation from these conditions can cause detrimental changes to metabolism and body composition. In contrast to weight loss from inadequate caloric intake, cachexia causes mostly muscle loss instead of fat loss. Diagnosis of cachexia can be difficult due to the lack of well-established diagnostic criteria. Cachexia can improve with treatment of the underlying illness but other treatment approaches have limited benefit. Cachexia is associated with increased mortality and poor quality of life.
The term is from Greek κακός kakos, "bad", and ἕξις hexis, "condition".
Cachexia can be caused by diverse medical conditions, but is most often associated with end-stage cancer, known as cancer cachexia. About 50% of all cancer patients suffer from cachexia. Those with upper gastrointestinal and pancreatic cancers have the highest frequency of developing a cachexic symptom. Prevalence of cachexia rises in more advanced stages and is estimated to affect 80% of terminal cancer patients.
Congestive heart failure, AIDS, chronic obstructive pulmonary disease, and chronic kidney disease are other conditions that often cause cachexia. Cachexia can also be the result of advanced stages of cystic fibrosis, multiple sclerosis, motor neuron disease, Parkinson's disease, dementia, tuberculosis, multiple system atrophy, mercury poisoning, Crohn's disease, rheumatoid arthritis, and celiac disease as well as other systemic diseases.
The exact mechanism in which these diseases cause cachexia is poorly understood, and likely is multifactorial with multiple disease pathways involved. Inflammatory cytokines appear to play a central role including TNF-alpha (which is also nicknamed 'cachexin' or 'cachectin'), interferon gamma and interleukin 6. TNF-alpha has been shown to have direct catabolic effect on skeletal muscle and adipose tissue through the ubiquitin proteasome pathway. This mechanism involves the formation of reactive oxygen species leading to upregulation of the transcription factor NF-κB. NF-κB is a known regulator of the genes that encode cytokines and cytokine receptors. The increased production of cytokines induces proteolysis and breakdown of myofibrillar proteins. Systemic inflammation also causes reduced protein synthesis through inhibition of the Akt/mTOR pathway.
Although many different tissues and cell types may be responsible for the increase in circulating cytokines, evidence indicates tumors themselves are an important source of factors that may promote cachexia in cancer. Tumor-derived molecules such as lipid mobilizing factor, proteolysis-inducing factor, and mitochondrial uncoupling proteins may induce protein degradation and contribute to cachexia. Uncontrolled inflammation in cachexia can lead to an elevated resting metabolic rate, further increasing the demands for protein and energy sources.
There is also evidence of alteration in feeding control loops in cachexia. High levels of leptin, a hormone secreted by adipocytes, block the release of neuropeptide Y, which is the most potent feeding-stimulatory peptide in the hypothalamic orexigenic network, leading to decreased energy intake despite the high metabolic demand for nutrients.
Diagnostic guidelines and criteria have only recently been proposed despite the prevalence of cachexia and varying criteria, the primary features of cachexia include progressive depletion of muscle and fat mass, reduced food intake, abnormal metabolism of carbohydrate, protein, and fat, reduced quality of life, and increased physical impairment.
Historically, body weight changes were used as the primary metrics of cachexia, including low body mass index and involuntary weight loss of more than 10%. Using weight alone is limited by the presence of edema, tumor mass and the high prevalence of obesity in the general population. Weight-based criteria do not take into account changes in body composition, especially loss of lean body mass.
In the attempt to include a broader evaluation of the burden of cachexia, diagnostic criteria using assessments of laboratory metrics and symptoms in addition to weight have been proposed. The criteria included weight loss of at least 5% in 12 months or low body mass index (less than 22 kg/m2) with at least three of the following features: decreased muscle strength, fatigue, anorexia, low fat‐free mass index, or abnormal biochemistry (increased inflammatory markers, anemia, low serum albumin).
Laboratory markers are used in evaluation of people with cachexia, including albumin, prealbumin, C-reactive protein, or hemoglobin. However, laboratory metrics and cut-off values are not standardized across different diagnostic criteria. Acute phase reactants (IL-6, IL-1b, tumor necrosis factor-a, IL-8, interferon-g) are sometimes measured but correlate poorly with outcomes. There are no biomarkers to identify people with cancer who may develop cachexia.
In the effort to better classify cachexia severity, several scoring systems have been proposed including the Cachexia Staging Score (CSS) and Cachexia Score (CASCO). The CSS takes into account weight loss, subjective reporting of muscle function, performance status, appetite loss, and laboratory changes to categorize patients into non-cachexia, pre-cachexia, cachexia and refractory cachexia. The Cachexia SCOre (CASCO) is another validated score that includes evaluation of body weight loss and composition, inflammation, metabolic disturbances, immunosuppression, physical performance, anorexia, and quality of life.
Evaluation of changes in body composition is limited by the difficulty in measuring muscle mass and health in a non-invasive and cost-effective way. Imaging with quantification of muscle mass has been investigated including bioelectrical impedance analysis, computed tomography, Dual-energy X-ray absorptiometry (DEXA), and magnetic resonance imaging but are not widely used.
Identification, treatment and research of cachexia has historically been limited by the lack of a widely accepted definition of cachexia. In 2011, an international consensus group adopted a definition of cachexia as “a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that can be partially but not entirely reversed by conventional nutritional support.”
Cachexia differs from weight loss due to malnutrition from malabsorption, anorexia nervosa, or anorexia due to major depressive disorder. Weight loss from inadequate caloric intake generally causes fat loss before muscle loss, whereas cachexia causes predominantly muscle wasting. Cachexia is also distinct from sarcopenia, or age-related muscle loss, although they often co-exist.
The management of cachexia depends on the underlying cause, the general prognosis, and needs of the person affected. The most effective approach to cachexia is treating the underlying disease process. An example is the reduction in cachexia from AIDS by highly active antiretroviral therapy. However this is often not possible or may be inadequate to reverse the cachexia syndrome in other diseases. Approaches to mitigate the muscle loss include exercise, nutritional therapies, and medications.
Therapy that includes regular physical exercise is recommended for the treatment of cachexia due to the positive effects of exercise on skeletal muscle. Individuals with cachexia generally report low levels of physical activity and few engage in an exercise routine, owing to low motivation to exercise and a belief that exercising may worsen their symptoms or cause harm.
Appetite stimulant medications are used to treat cachexia to increase food intake, but are not effective in stopping muscle wasting and may have detrimental side effects. Appetite stimulants include glucocorticoids, cannabinoids, or progestins such as megestrol acetate. Anti-emetics such as 5-HT3 antagonists are also commonly used in cancer cachexia if nausea is a prominent symptom.
Anabolic-androgenic steroids like oxandrolone may be beneficial in cachexia but their use is recommended for a maximum of two weeks since a longer duration of treatment increases side effects.
The increased metabolic rate and appetite suppression common in cachexia can compound muscle loss. Studies using a calorie-dense protein supplementation have suggested at least weight stabilization can be achieved, although improvements in lean body mass have not been observed in these studies.
Administration of exogenous amino acids have been investigated to serve as a protein-sparing metabolic fuel by providing substrates for both muscle metabolism and gluconeogenesis. The branched-chain amino acids leucine and valine may have potential in inhibiting overexpression of protein breakdown pathways. The amino acid glutamine has been used as a component of oral supplementation to reverse cachexia in people with advanced cancer or HIV/AIDS.
β-hydroxy β-methylbutyrate (HMB) is a metabolite of leucine that acts as a signaling molecule to stimulate protein synthesis. Studies showed positive results for chronic pulmonary disease, hip fracture, and in AIDS‐related and cancer‐related cachexia. However, many of these clinical studies used HMB as a component of combination treatment with glutamine, arginine, leucine, higher dietary protein and/or vitamins, which limits the assessment of the efficacy of HMB alone.
Accurate epidemiological data on the prevalence of cachexia is lacking due to changing diagnostic criteria and under-identification of people with the disorder. It is estimated that cachexia from any disease is estimated to affect more than 5 million people in the United States. The prevalence of cachexia is growing and estimated at about 1% of the population. The prevalence is lower in Asia but due to the larger population, represents a similar burden. Cachexia is also a significant problem in South America and Africa.
The most frequent causes of cachexia in the United States by population prevalence are: 1) COPD, 2) heart failure, 3) cancer cachexia, 4) chronic kidney disease. The prevalence of cachexia ranges from 15–60% among people with cancer, increasing to an estimated 80% in terminal cancer. This wide range is attributed to differences in cachexia definition, variability in cancer populations, and timing of diagnosis. Although the prevalence of cachexia among people with COPD or heart failure is lower (estimated 5% to 20%), the large number of people with these conditions dramatically increases the total cachexia burden.
Cachexia contributes to significant loss of function and healthcare utilization. Estimates using the National Inpatient Sample in the United States suggest that cachexia accounted for 177,640 hospital stays in 2016. Cachexia is considered the immediate cause of death of many people with cancer, estimated between 22-40%.
Several medications are under investigation or have been previously trialed for use in cachexia but are currently not in widespread clinical use:
- Cytokine antagonists
- Omega-3 fatty acids, including eicosapentaenoic acid (EPA)
- Non-steroidal anti-inflammatory drugs
- Ghrelin and ghrelin receptor agonist
- Anabolic catabolic transforming agents such as MT-102
- Selective androgen receptor modulators
Medical marijuana has been allowed for the treatment of cachexia in some US states, such as Illinois, Maryland, Delaware, Nevada, Michigan, Washington, Oregon, California, Colorado, New Mexico, Arizona, Vermont, New Jersey, Rhode Island, Maine, and New York  Hawaii and Connecticut.
Despite the extensive investigation into single therapeutic targets for cachexia, the most effective treatments use multi-targeted therapies. In Europe, a combination of non-drug approaches including physical training, nutritional counseling, and psychotherapeutic intervention are used in belief this approach may be more effective than monotherapy. Administration of anti-inflammatory drugs showed efficacy and safety in the treatment of people with advanced cancer cachexia.
- "Cachexia | Definition of Cachexia by Lexico". Lexico Dictionaries | English.
- Fearon KC, Moses AG (September 2002). "Cancer cachexia". International Journal of Cardiology. 85 (1): 73–81. doi:10.1016/S0167-5273(02)00235-8. PMID 12163211.
- Ebner N, Springer J, Kalantar-Zadeh K, Lainscak M, Doehner W, Anker SD, von Haehling S (July 2013). "Mechanism and novel therapeutic approaches to wasting in chronic disease". Maturitas. 75 (3): 199–206. doi:10.1016/j.maturitas.2013.03.014. PMID 23664695.
- Meresse B, Ripoche J, Heyman M, Cerf-Bensussan N (January 2009). "Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis". Mucosal Immunology. 2 (1): 8–23. doi:10.1038/mi.2008.75. PMID 19079330.
- Morley JE, Thomas DR, Wilson MM (April 2006). "Cachexia: pathophysiology and clinical relevance". The American Journal of Clinical Nutrition. 83 (4): 735–43. doi:10.1093/ajcn/83.4.735. PMID 16600922.
- Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G (December 2010). "Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment". Current Treatment Options in Oncology. 11 (3–4): 107–17. doi:10.1007/s11864-010-0127-z. PMC 3016925. PMID 21128029.
- Argilés, Josep M.; Campos, Nefertiti; Lopez-Pedrosa, José M.; Rueda, Ricardo; Rodriguez-Mañas, Leocadio (2016). "Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease". Journal of the American Medical Directors Association. 17 (9): 789–796. doi:10.1016/j.jamda.2016.04.019. ISSN 1538-9375. PMID 27324808.
- Martignoni ME, Kunze P, Friess H (November 2003). "Cancer cachexia". Molecular Cancer. 2 (1): 36. doi:10.1186/1476-4598-2-36. PMC 280692. PMID 14613583.
- Peterson SJ, Mozer M (February 2017). "Differentiating Sarcopenia and Cachexia Among Patients With Cancer". Nutrition in Clinical Practice. 32 (1): 30–39. doi:10.1177/0884533616680354. PMID 28124947.
- Dev R (January 2019). "Measuring cachexia-diagnostic criteria". Annals of Palliative Medicine. 8 (1): 24–32. doi:10.21037/apm.2018.08.07. PMID 30525765.
- Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. (December 2008). "Cachexia: a new definition". Clinical Nutrition. 27 (6): 793–9. doi:10.1016/j.clnu.2008.06.013. PMID 18718696.
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. (May 2011). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. 12 (5): 489–95. doi:10.1016/s1470-2045(10)70218-7. PMID 21296615.
- DHHS, 2009. "Care Management Guidelines Fatigue, Anorexia and Cachexia" (PDF). Archived from the original (PDF) on 2014-05-14. Retrieved 23 February 2014.
- "AIDS Wasting Syndrome". WebMD.
- Grande AJ, Silva V, Riera R, Medeiros A, Vitoriano SG, Peccin MS, Maddocks M (November 2014). "Exercise for cancer cachexia in adults". The Cochrane Database of Systematic Reviews (11): CD010804. doi:10.1002/14651858.CD010804.pub2. PMID 25424884.
- Grande AJ, Silva V, Maddocks M (September 2015). "Exercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic review". Journal of Cachexia, Sarcopenia and Muscle. 6 (3): 208–11. doi:10.1002/jcsm.12055. PMC 4575551. PMID 26401466.
- Ferioli M, Zauli G, Martelli AM, Vitale M, McCubrey JA, Ultimo S, Capitani S, Neri LM (March 2018). "Impact of physical exercise in cancer survivors during and after antineoplastic treatments". Oncotarget. 9 (17): 14005–14034. doi:10.18632/oncotarget.24456. PMC 5862633. PMID 29568412.
- Wasley D, Gale N, Roberts S, Backx K, Nelson A, van Deursen R, Byrne A (February 2018). "Patients with established cancer cachexia lack the motivation and self-efficacy to undertake regular structured exercise" (PDF). Psycho-Oncology. 27 (2): 458–464. doi:10.1002/pon.4512. PMID 28758698.
- Gagnon B, Bruera E (May 1998). "A review of the drug treatment of cachexia associated with cancer". Drugs. 55 (5): 675–88. doi:10.2165/00003495-199855050-00005. PMID 9585863.
- European Palliative Care Research Collaborative. "New European Guidelines: CLINICAL PRACTICE GUIDELINES ON CANCER CACHEXIA IN ADVANCED CANCER PATIENTS". Archived from the original on 2 May 2014. Retrieved 23 February 2014.
- Giovanni Mantovani (6 October 2007). Cachexia and Wasting: A Modern Approach. Springer Science & Business Media. pp. 673–. ISBN 978-88-470-0552-5.
- Eley HL, Russell ST, Tisdale MJ (October 2007). "Effect of branched-chain amino acids on muscle atrophy in cancer cachexia". The Biochemical Journal. 407 (1): 113–20. doi:10.1042/BJ20070651. PMC 2267397. PMID 17623010.
- May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN (April 2002). "Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine". American Journal of Surgery. 183 (4): 471–9. doi:10.1016/s0002-9610(02)00823-1. PMID 11975938.
- "Glutamine". WebMD. WebMD, LLC. Retrieved 2015-03-15.
- Brioche T, Pagano AF, Py G, Chopard A (August 2016). "Muscle wasting and aging: Experimental models, fatty infiltrations, and prevention". Molecular Aspects of Medicine. 50: 56–87. doi:10.1016/j.mam.2016.04.006. PMID 27106402.
- Holeček, Milan (Aug 2017). "Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions: HMB supplementation and muscle". Journal of Cachexia, Sarcopenia and Muscle. 8 (4): 529–541. doi:10.1002/jcsm.12208. PMC 5566641. PMID 28493406.
- von Haehling S, Anker SD (September 2010). "Cachexia as a major underestimated and unmet medical need: facts and numbers". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 1–5. doi:10.1007/s13539-010-0002-6. PMC 3060651. PMID 21475699.
- Barrett ML, Bailey MK, Owens PL. Non-maternal and Non-neonatal Inpatient Stays in the United States Involving Malnutrition, 2016. ONLINE. August 30, 2018. U.S. Agency for Healthcare Research and Quality. Available: https://www.hcup-us.ahrq.gov/reports/HCUPMalnutritionHospReport_083018.pdf.
- Alhamarneh O, Agada F, Madden L, Stafford N, Greenman J (March 2011). "Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma". Head & Neck. 33 (3): 415–23. doi:10.1002/hed.21464. PMID 20645289.
- Argilés JM, Busquets S, López-Soriano FJ (September 2011). "Anti-inflammatory therapies in cancer cachexia". European Journal of Pharmacology. 668 Suppl 1: S81–6. doi:10.1016/j.ejphar.2011.07.007. PMID 21835173.
- Ries A, Trottenberg P, Elsner F, Stiel S, Haugen D, Kaasa S, Radbruch L (June 2012). "A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project" (PDF). Palliative Medicine. 26 (4): 294–304. doi:10.1177/0269216311418709. PMID 21865295.
- Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A (May 2013). "Cancer cachexia--pathophysiology and management". Journal of Gastroenterology. 48 (5): 574–94. doi:10.1007/s00535-013-0787-0. PMC 3698426. PMID 23512346.
- "Program Information and News - New York State Medical Marijuana Program". www.health.ny.gov.
- Rules Governing the Maine Medical Use of Marijuana Program - 10-144 CMR Chapter 122 - Section 3.1.3
- "Medical Marijuana Registry Program | Eligible Debilitating Medical Conditions". health.hawaii.gov. Archived from the original on 2016-05-22. Retrieved 2016-04-27.
- Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R (November 2005). "Systematic review of the treatment of cancer-associated anorexia and weight loss". Journal of Clinical Oncology. 23 (33): 8500–11. doi:10.1200/JCO.2005.01.8010. PMID 16293879.
- Scientists find key to "wasting syndrome" seen in cancer, AIDS (U.S. Department of Veterans Affairs)
|Look up cachexia in Wiktionary, the free dictionary.|